It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Our Direct‑to‑Discovery platform accelerates Hit‑to‑Lead by generating biological, structural, and key DMPK data directly from crude reaction mixtures (CRMs), bypassing purification. By extending Direct‑to‑Biology (D2B) with broader data generation at the same early stage, it enables faster, more confident, and more cost‑effective decision‑making.
The average timeline from validated hit to preclinical candidate delivery in drug discovery is approximately four years. To shorten this timespan, Direct‑to‑Biology strategies are increasingly employed to accelerate early decision‑making and advance compound progression.
Our approach, Direct‑to‑Discovery, extends this even further, integrating not just chemistry and biology, but also DMPK and structural biology earlier into the process.
Harnessing the expertise of our high-throughput chemistry team, we reliably identify and validate assay compliant conditions across diverse reaction types. Coupled with our deep understanding of assay endpoints for CRMs, we deliver data that accelerates early decision making and drives compound progression.
Standard D2B workflows often focus primarily on affinity or efficacy measurements from CRMs, overlooking the broader value of this rich data source. To unlock this potential, we have expanded the approach through integrated methods, including Direct-to-Crystallography (D2C) and Direct–to-Physiochemistry and DMPK (D2DMPK), providing molecular level binding insight and detailed SAR directly from CRMs.
Feeding all this information into machine learning models completes the DMTA cycle and supports the use of AI to design future modifications.
Direct-to-Biology Expertise
At Sygnature, we take a connected approach to compound optimisation, breaking down disciplinary silos to deliver better outcomes for our customers. This collaboration is essential for Direct‑to‑Biology, where understanding the composition of a CRM, and how it influences assay readouts, is critical for selecting the most appropriate chemistry and target dependant endpoint.
A forensic, connected mindset
The same forensic mindset underpins our Direct‑to‑Crystallography (D2C) and Direct‑to‑Physiochemistry and DMPK (D2DMPK) approaches. By integrating expertise across functions, we generate high‑quality data with both speed and precision.
Applying the strategy at the right time
The value of these techniques hinges on recognising when to apply this strategy as well as designing well‑targeted libraries.
Libraries designed for decision‑making
Our teams combine medicinal chemistry knowledge with AI and ML to craft compound sets that deliver decision‑making insights. These insights drive better compound design and faster progress toward pre‑clinical candidate delivery.
Key Strengths
These capabilities work together to form our broader Direct‑to‑Discovery model, which unites not only chemistry and biology but also structural biology and DMPK for a more connected discovery process.
Assay-Ready Chemistry
Reactions designed for bioassey compatibility from the outset.
Automated High-Throughput Synthesis
96- and 384-well formats feeding directly into screening workflows.
Flexible bioassay integration
biochemical, biophysical, and cellular assays set up to handle crude or minimally purified material when appropriate
Real Time Structural Insights
D2C workflows that refine SAR with speed and accuracy.
Fast Metabolic Stability Readouts
D2DMPK to inform on metabolic stability and further rank compounds.
Fully Integrated Degrader Discovery
Connecting straight into our CHARMED platform for molecular glue and PROTAC design.
Typical Applications
Fragment-based Drug Discovery – Integrating D2B and D2C to accelerate the identification of novel protein binders.
Early hitexpansion – A data‑intensive phase of drug discovery where the rapid generation of SAR using D2B can be exceptionally powerful.
Rapid SAR generation during Hit to Lead or Lead Optimization – Enables fast, efficient use of resources and accelerates optimisation at any stage of the programme.
Targeted proteindegradation – Provides the throughput needed to uncover new molecular glues and PROTACs, which are challenging to design using traditional methods.
Why Choose Sygnature Discovery for Direct to Biology Support?
Our Direct-to-Discovery platform isn’t just about going faster; it’s about changing the cadence of discovery. When chemical synthesis, biological testing, structural information and DMPK profiling run essentially in parallel:
Hit expansion accelerates – chemistry output can be triaged immediately, prioritizing the most promising analogues for full synthesis and purification
Decision points come earlier – unproductive chemical space is abandoned sooner, conserving resources
Biology drives chemistry – assay results feed directly back into design, guiding the next synthetic steps with live data
The result: weeks compressed into days, and SAR intelligence generated in near real-time.
PROTACs, formally known as heterobifunctional degraders, remain an exciting modality for…
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.
Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.
Transforming early leads into clinical-quality candidates through integrated expertise, rapid decision-making, and optimized strategies for safety, potency, and exposure.
Automated high-throughput chemistry delivering rapid, high-quality compound libraries enabling efficient SAR exploration and faster progression from concept to candidate.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
Targeted Protein Degradation (TPD) is an innovative drug discovery approach focused on previously considered ‘undruggable’ proteins. TPD leverages the cell’s ubiquitin-proteasome system to tag these ‘undruggable’ proteins for degradation.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
